title: Effects of vascular endothelial growth factor on wound closure rates in the genetically diabetic mouse model.
abstract: Impaired wound healing is characteristic of diabetic patients. Potential reasons include poor inflammatory response, granulation tissue formation, and abnormal patterns of cytokine release and response. Vascular endothelial growth factor, abnormally regulated during healing in diabetics, is the major factor stimulating angiogenesis during normal wound healing. We tested our hypothesis that topically applied vascular endothelial growth factor would improve wound closure rates in diabetic animals in a full-thickness wound model in genetically diabetic mice (C57 BL/KsJ db/db). Animals received either 1.0 micro g of vascular endothelial growth factor165 or polyethylene glycol alone topically to wounds daily between days 0 and 4 post-wounding. Wound area was measured at days 0, 5, 10, 15, and 21. Data were analyzed using probit analysis and expressed as length-of-time (LT) to 50, 90, and 95% wound closure. Among untreated animals, nondiabetics had an LT50 of 8.5 days (fiducial limits 8.3-8.7), while diabetics had an LT50 of 15.8 days (15.6-16.1). Vascular endothelial growth factor-treated animals had LT50 values of 7.8 (7.6-8.1) and 11.8 days (11.6-12.0) for nondiabetics and diabetics, respectively, representing a 25% improvement in time to 50% closure in treated diabetics. We conclude that topically applied vascular endothelial growth factor improves time to wound closure in the genetically diabetic mouse model.
authors.affiliation: Northeastern Ohio Universities College of Medicine, Affiliated Hospitals at Canton, Ohio, USA.
authors.forename: Loren M
authors.initials: LM
authors.lastname: Kirchner
authors.forename: Sharon O
authors.initials: SO
authors.lastname: Meerbaum
authors.forename: Brian S
authors.initials: BS
authors.lastname: Gruber
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Knoll
authors.forename: Jeffery
authors.initials: J
authors.lastname: Bulgrin
authors.forename: R A J
authors.initials: RA
authors.lastname: Taylor
authors.forename: Steven P
authors.initials: SP
authors.lastname: Schmidt
mesh_terms: D000287:Administration, Topical; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage*; D000818:Animals; D003920:Diabetes Mellitus / Q000503:physiopathology*; D016228:Endothelial Growth Factors / Q000008:administration & dosage*; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage*; D008222:Lymphokines / Q000008:administration & dosage*; D051379:Mice; D023421:Models, Animal; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D043925:Angiogenesis Inducing Agents; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors